Irinotekanijev Klorid Kabi (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is metabolised inside cells to SN‑38, an active metabolite that binds to the DNA‑topoisomerase I complex. By stabilising this complex, it prevents the re‑ligation of single‑strand DNA breaks during replication, leading to accumulation of DNA damage, cell‑cycle arrest and ultimately tumour cell death.

The dose of Irinotekanijev Klorid Kabi is individualized and determined by the prescribing oncologist based on factors such as cancer type, treatment protocol, patient weight, organ function and prior therapy. No fixed dosing information is provided here; clinicians set the regimen according to established guidelines.

Irinotecan is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should only be used during pregnancy when the potential benefit justifies the risk. Breastfeeding is not recommended because the drug can be excreted in milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Irinotecan and topotecan are the two main topoisomerase I inhibitors used in oncology. Irinotecan is typically employed for colorectal and certain solid tumours, while topotecan is more common in ovarian and small‑cell lung cancer. Both share a similar mechanism but differ in pharmacokinetics, toxicity profiles and approved indications.

The injectable solution should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to administration, the product should be inspected for particulate matter and used within the time frame specified in the manufacturer’s labeling.

Irinotekanijev Klorid Kabi is given by intravenous infusion. The solution is diluted according to the prescribing information and infused over a defined period, usually 30‑90 minutes, under medical supervision. Infusion rates may be adjusted based on patient tolerance and clinical response.

The most serious adverse events include severe neutropenia with risk of infection, febrile neutropenia, life‑threatening diarrhoea (including colitis or bowel perforation), hepatic toxicity, and rare allergic reactions such as anaphylaxis. Prompt monitoring and supportive care are essential to manage these risks.

Patients with known hypersensitivity to irinotecan or any component of the formulation should avoid the product. It is also contraindicated in individuals with severe bone‑marrow suppression, uncontrolled infections, or those who are pregnant unless the therapeutic benefit outweighs the risk. Clinical judgment is required for other special populations.